Agios Pharmaceuticals AGIO Proceeds From Sale And Maturity Of Available For Sale Securities
Proceeds From Sale And Maturity Of Available For Sale Securities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's proceeds from sale and maturity of available for sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
- Agios Pharmaceuticals (AGIO) reported proceeds from sale and maturity of available for sale securities of $290.26M in Q1 2026.
- How has Agios Pharmaceuticals's proceeds from sale and maturity of available for sale securities changed year-over-year?
- Agios Pharmaceuticals's proceeds from sale and maturity of available for sale securities increased by 0.7% year-over-year, from $288.26M to $290.26M.
- What is the long-term trend for Agios Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's proceeds from sale and maturity of available for sale securities has grown at a 5.6% compound annual growth rate (CAGR), from $829.8M to $1.03B.